⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327784 | 1.00 | — | — | |
| SCHEMBL1299627 | 1.00 | — | — | |
| Iodide SCHEMBL38651116 | 0.98 | — | — | |
| SCHEMBL14087966 | 0.93 | — | — | |
| SCHEMBL88583 | 0.93 | — | — | |
| SCHEMBL12018255 | 0.93 | — | — | |
| SCHEMBL18967338 | 0.91 | CHRM1 (0.45) | — | |
| SCHEMBL31029450 | 0.84 | — | — | |
| SCHEMBL2089866 | 0.84 | — | — | |
| SCHEMBL30315163 | 0.78 | CHRM1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117347527-A | Detection method of N-methyl-L-prolyl related substances | 江苏威奇达药业有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-111018767-B | Preparation method of D-proline derivative and intermediate thereof | 江苏美迪克化学品有限公司 | 2021-09-28 | — | — | CN | claimed |
| CN-111018767-A | Preparation method of D-proline derivative and intermediate thereof | 江苏美迪克化学品有限公司 | 2020-04-17 | — | — | CN | claimed |
| JP-4508413-B2 | — | — | 2010-07-21 | — | — | JP | claimed |
| US-7662786-B2 | oligopeptides; anticarcinogenic agent; good water solubility and cost effective; , B, D, E, F, G and K are alpha -amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as,an amino group, an N-substituted amino group, a beta -hydroxylamino group, an alkoxy group | ABBOTT GMBH & CO. KG (DE) | 2010-02-16 | — | — | US | claimed |
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | claimed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | claimed |
| US-20060270606-A1 | Dolastatin 15 derivatives | ABBOTT GMBH & CO., KG (DE) | 2006-11-30 | — | — | US | claimed |
| CN-1268636-C | Dolastatin 15 derivatives | ABSF AG (DE) | 2006-08-09 | — | — | CN | claimed |
| EP-0991658-B1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO KG (DE) | 2005-12-28 | — | — | EP | claimed |
| EP-1232183-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2002-08-21 | — | — | EP | claimed |
| CN-1312817-A | Dolastatin 15 derivatives | BASF AG (DE) | 2001-09-12 | — | — | CN | claimed |
| US-20010018422-A1 | Dolastatin 15 derivatives | BASF AKTIENGESELLSCHAFT | 2001-08-30 | — | — | US | claimed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001038347-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| US-6143721-A | FOR TREATING CANCER IN MAMMALS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | claimed |
| CN-1264388-A | Dolastatin 15 derivatives | ABSF AG (DE) | 2000-08-23 | — | — | CN | claimed |
| EP-0991658-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-12 | — | — | EP | claimed |
| US-5985837-A | CELL GROWTH INHIBITOR PEPTIDES; TREATING CANCER IN A MAMMAL | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-16 | — | — | US | claimed |
| WO-1999003879-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-28 | — | — | WO | claimed |